Paul Offit of the Perelman School of Medicine spoke about the FDA’s emergency authorization of hydroxychloroquine as a COVID-19 treatment, despite a lack of evidence of its efficacy. “I think the administration bent or imposed its will on the F.D.A.,” he said. “There’s a concern that this would happen [with the vaccine], too.”